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Introduction
Pulmonary hypertension in left heart disease (PH-LHD) 
commonly complicates prolonged heart failure (HF). 
Patients undergoing orthotopic heart transplant (OHT) 
with PH-LHD, and specifically out of proportion PH, 
which is a combination of pre-and post-capillary PH, 
have increased morbidity and mortality. An elevated 
pulmonary vascular resistance (PVR) >2.5 Wood units 
results in a nearly 30% increase in mortality within the first 
month post-transplant (1,2). In this review, we examine 
the data published between January, 1990 to present day 
regarding the definition and prognosis of this disease as 
well as both medical and mechanical support therapeutic 
strategies. The only guideline recommended treatment 
of PH-LHD is aimed at treating the underlying HF by 
reducing the pulmonary capillary wedge pressure (PCWP) 
and potentially allowing the normalization of PVR over 
time. These treatments for HF are well established 
and include diuretics, angiotensin converting enzyme 
inhibitors (ACE-I), angiotensin receptor blockers (ARBs), 
mineralocorticoid receptor antagonists, ARB/neprilysin 
inhibitor, beta-blockers, and in certain populations, non-
specific vasodilators such as nitrates and hydralazine. In 
patients with low cardiac output, inotropic drugs may be 
required. For patients with longstanding HF, mechanical 
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support with left ventricular assist devices (LVAD) has 
demonstrated a benefit by unloading the left ventricle 
(LV) and normalizing PVR, especially in candidates for 
OHT (3,4).
Some medications used for the treatment of World 
Health Organization (WHO) group 1 pulmonary arterial 
hypertension (WHO PAH classification, Table 1) have 
been employed off-label in the setting of WHO group 2 
PH-LHD, perhaps driven by the hypothesis that there is 
a significant PAH-like component in out of proportion 
PH. These studies have demonstrated variable efficacy 
and often negative outcomes in a strategy to optimize the 
PVR pre-OHT. Specifically, the use of guanylyl cyclase 
pathway modulators, including phosphodiesterase 5 
(PDE-5) inhibitors appear to be more successful than 
others, especially in the peri-operative period.
Definition of pulmonary hypertension
PH is a frequent comorbidity in patients with prolonged 
HF. Nearly two thirds of patients with HF with reduced 
ejection fraction (HFrEF) and HF with preserved ejection 
fraction (HFpEF) have PH (5). Comorbid PH in patients 
with HFrEF increases risk of HF hospital admissions and 
in patients with HFpEF it is associated with an increase in 
5-year all-cause mortality (6). In patients with advanced 
HF, the mechanism of PH is related to a post-capillary and 
passive rise in mean pulmonary artery pressure (mPAP) 
resulting from a back-transmission of elevated LV diastolic 
pressure (7). This type of PH is defined invasively by mPAP 
>25 mmHg, and PCWP >15 mmHg, with a diastolic 
pressure gradient (DPG; defined as diastolic PA pressure—
mean PCWP) <7 mmHg (3). 
In patients with prolonged HF and WHO Group 2 
PH, the subtype of combined pre-and post-capillary PH, 
as defined at mPAP >25 mmHg, PCWP >15 mmHg, and 
DPG >7, is frequently present. In addition to the passive 
rise in mPAP resulting from increased LV hydrostatic 
pressures (post-capillary PH), the pre-capillary component 
has characteristics of WHO group 1 PH, in which there is 
vascular remodeling due to multiple pathologic changes in 
biochemical signaling: a decrease in endogenous nitric oxide 
(NO), increased endothelin expression, and desensitization 
to natriuretic peptide induced vasodilatation (3). These 
pathophysiologic mechanisms result in elevation of mPAP 
in excess of PCWP, giving the names of “fixed”, “out 
of proportion”, “mixed” or “combined pre-and post-
capillary” PH to this disease entity. Throughout this 
review we will employ the term “out of proportion” PH. 
Hemodynamically, this is characterized by a PVR >5 Wood 
units, transpulmonary gradient (TPG) [mPAP minus 
the PCWP] >15 mmHg, non-reversible hemodynamics 
by administration of pulmonary vasodilators such as 
nitroprusside (8,9). Further stratification of patients with 
mixed PH as those having increased or normal pulmonary 
DPG may have treatment and prognostic significance, with 
a DPG >7 mmHg indicating advanced pulmonary vascular 
remodeling and mixed pre-and post-capillary PH (3,10,11). 
PH in advanced HF and clinical outcomes
The presence of out of proportion PH has clinical and 
prognostic significance for patients with longstanding HF 
being considered for OHT due to elevated PVR, chronic 
RV overload, and an increased risk of post-transplant right 
HF. This has negatively impacted survival in the first year 
post transplant (1). Current International Society for Heart 
and Lung Transplantation (ISHLT) guidelines consider 
PH that is not readily reversible by pulmonary vasodilators, 
or “fixed PH”, to be a relative contraindication to OHT 
(12-14). A review of the Cardiac Transplant Research 
Database (CTRD) consisting of patient data from 26 US 
institutions from the past 20 years reveals that the overall 
risk of death after OHT has decreased and, in particular, 
the contribution of elevated PVR to increased mortality 
has declined over time from over 10% to less than 5% 
at one year post transplant (15). Similar trends in post-
OHT outcomes are also observed from the Registry of 
ISHLT (16). A reason for this important trend could be 
Table 1 WHO classification of PH
WHO group Definition
Group 1 PAH: idiopathic, heritable, drug-related, and 
connective tissue PAH (such as scleroderma), 
portopulmonary, HIV, schistosomiasis
Group 2 Pulmonary hypertension secondary to left heart 
disease: diastolic HF, systolic HF, valvular HF
Group 3 PH due to chronic lung disease and/or chronic 
hypoxemia
Group 4 Chronic thromboembolic disease
Group 5 PH which is multifactorial
WHO, World Health Organization; PH, pulmonary hypertension; 
PAH,  pu lmonary  a r te r i a l  hyper tens ion ;  H IV,  human 
immunodeficiency virus; HF, heart failure.
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the result of a combination of guideline directed treatment 
for Group 2 PH (4) as well as institution-specific use of 
off-label Group 1 PH therapies (17) in select patients 
with a normalization of PCWP on medical or mechanical 
circulatory assist therapy. We will focus on the studies 
to date that have examined the efficacy and outcomes of 
Group 1 PH therapies in patients with Group 2 PH. Where 
sufficient data is available, the discussion of treatment of 
Group 2 PH will emphasize three categories of patients: 
patients with HF (irrespective of presence of PH), patients 
with HF and PH, and patient with HF and PH undergoing 
optimization for OHT.
Treatment of PH-LHD
Vasodilators—inhaled and intravenous 
Pulmonary selective vasodilators have been used for several 
decades in the treatment of longstanding PH-LHD. 
Their use in the acute setting has been validated by basic 
and clinical science, but with no randomized controlled 
studies showing a definitive benefit (18,19). These agents 
act as selective pulmonary vasodilators by increasing cyclic 
guanosine monophosphate resulting in an improvement 
of ventilation-perfusion matching and a reduction in 
PVR, although as a class there may be a less pronounced 
effect on lowering TPG (17,20). Most commonly used 
are inhaled nitric oxide (NO) and inhaled prostacyclins 
(for example, iloprost). Both medications may be useful in 
the acute peri-operative setting in patients with HF and 
PH (21-23). Argenziano et al. [1998] randomized 11 of 23 
consecutive patients post LVAD placement who met criteria 
for elevated PVR to either NO or inhaled nitrogen therapy. 
Significantly, only the 6 patients who received NO exhibited 
significant reductions in mean PA pressure from 35±6 to 
24±4 mmHg while the 5 patients receiving inhaled nitrogen 
had no significant change in mean PA pressure (21). In a 
study comparing NO and inhaled prostacyclin in post-OHT 
and post lung transplant patients, both agents were found to 
similarly reduce mPAP, central venous pressure and improve 
cardiac index (CI) (24). In a head to head comparison of 
NO and inhaled iloprost, a prostaglandin, in 46 patients 
being weaned from cardiopulmonary bypass, both agents 
reduced PVR, mPAP and increased cardiac output, with 
the latter agent being significantly more effective (25). 
Iloprost has some advantages over NO as there is no risk 
of methemoglobinemia or rebound PH with prolonged use 
(17,20). NO requires continuous inhalation given its very 
short half-life, with even a brief interruption resulting in 
rebound PH and potential RV failure. Iloprost may be given 
at doses of 5–10 mcg every 3–4 h and can be weaned off 
in the perioperative period (26). While current published 
studies suggest a clinical benefit in the perioperative setting, 
there is no evidence to support chronic therapy with inhaled 
vasodilators in HF or HF with PH patients given the cost 
and difficulty of administration.
Intravenous agents such as nitroglycerin and nitroprusside, 
both exogenous NO donors, are commonly used in the 
acute setting to assess reversibility of PH-LHD and as a 
bridge therapy to more definitive treatments (17,27,28). 
In a study of 33 patients with PH secondary to end-stage 
HF, the use of nesiritide, a synthetic B-type natriuretic 
peptide, during hospitalization for HF significantly reduced 
PCWP by 31% and mPAP by 15.6% compared to pre-
treatment (29). Michaels et al. [2005] studied 20 patients 
with HF and PH (mPA >25 mmHg): 10 with PCWP >15 
mmHg and 10 with PCWP ≤15. In the patients with what 
the researchers defined as post-capillary PH or PH with a 
PCWP >15, nesiritide infusion for 30 minutes decreased 
both the mPA pressure and PCWP, and significantly 
increased the CI (30). However, the long term therapeutic 
benefit of nesiritide in pre-OHT patients is uncertain. 
The intravenous form of epoprostenol appears to have 
benefit in selected patients in the peri- or post-transplant 
period but not as long term therapy prior to transplant 
while the patient has LV dysfunction. Califf et al. [1997], 
in The Flolan International Randomized Survival Trial 
(FIRST), enrolled 471 patients with New York Heart 
Association (NYHA) class IIIB or IV HF. With the use 
of intravenous epoprostenol, hemodynamic factors such 
as mPAP, PCWP, and PVR improved acutely however 
the long-term infusion not only failed to demonstrate 
clinical benefits but also showed a trend toward increased 
mortality (31). 
PDE-5 inhibitors and guanylyl cyclase agonists
The modulators of the guanylyl cyclase pathway in the 
endothelium have overall shown the greatest promise of 
treatment efficacy for PH-LHD. Redfield et al. [2013] 
studied the effect of sildenafil, a PDE-5 inhibitor on 
exercise capacity in 216 patients with HFpEF (EF >50%). 
The patients were randomized to receive either sildenafil 
or placebo for a total of 24 weeks. At 24 weeks peak oxygen 
consumption and change in 6-minute walk test were not 
significantly different between the two groups (32). Several 
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randomized trials are completed or currently underway 
studying the treatment efficacy of PDE-5 inhibitors in the 
PH-LHD population (Table 2). Within the same general 
class of guanylyl cyclase modulator therapies, novel guanylyl 
cyclase stimulators are showing promise. Riociguat is a 
soluble guanylate cyclase stimulator which demonstrated 
positive hemodynamic effects in 2 randomized trials by 
Bonderman et al. (2013 and 2014) in patients with HF and 
secondary PH. Although neither trial met the primary 
endpoint of change in mPAP, riociguat treatment did result 
in an increase in CI, stroke volume and decrease in systemic 
and peripheral vascular resistance (Table 2) (37,38). 
A study by Lewis et al. [2007] in patients with HF and PH 
demonstrated that the PDE-5 inhibitor sildenafil improved 
NYHA class, 6-minute walk distance, as well as significantly 
reduced hospitalizations for HF (40). In a retrospective 
study by de Groote et al. [2015] sildenafil use pre-OHT in 
18 patients resulted in a change in PVR at an average of 8.7 
months of treatment from 5.3±1.9 Wood units to 3.3±1.8 
Wood units (P=0.01). Five patients were able to proceed 
with successful OHT and 6 with left ventricular assist 
device (LVAD). All patients with a PVR <3 Wood units 
after treatment survived, with survival in the group with 
PVR >3 being only 44% (41). In addition, hemodynamic 
parameters such as RV ejection fraction, PVR, and peak 
oxygen consumption improved in this population of HF 
patients with WHO group 2 PH with the administration of 
sildenafil (41). The effect of sildenafil to optimize the PVR 
in 119 consecutive patients was studied at one institution 
by Pons et al. [2012]. Fifteen patients with a PVR >2.5 
Wood units and/or TPG >12 were treated with sildenafil 
pre-operatively with a target dose of 109±42 mg/day 
of sildenafil (titrated and administered as three times a day 
dosing) for 163±116 days prior to OHT. Hemodynamic 
parameters improved in these patients: mPAP, PVR, and 
TPG all decreased significantly in this group at risk for 
right HF post-OHT. Specifically, mPAP decreased from 
43.9±12.5 to 33.4±5.8 mmHg and PVR decreased from 
5±1.1 to 3±1.6 (P<0.01) Wood units in the 15 patients 
treated with sildenafil pre-operatively. Post-OHT mortality 
was comparable between the two groups of patients with 
and without severe PH-LHD in 6 month follow-up (42). 
Endothelin receptor antagonists (ERAs)
Endothelin is a potent endogenous vasoconstrictor with 
both pulmonary and systemic effects. It is upregulated 
in patients with prolonged HF and correlates with more 
severe PH, increased PVR, and worse survival outcomes. 
Preclinical and small clinical studies of ERA have shown 
improvements in hemodynamic parameters and morbidity. 
Administration of the non-specific endothelin receptor A 
and B (ETA and ETB) antagonist, bosentan, in a study of 
more than 80 end-stage HF patients, increased by 20% 
the number of eligible patients for OHT by reducing 
mPAP, PVR and TPG, as compared to the control group. 
One-year survival on the transplant waiting list was also 
significantly improved in this study (43). Despite initial 
encouraging results, randomized trials of a non-selective 
ERA, tezosentan, studied in the Randomized Intravenous 
Tezosentan (RITZ) trial and the Value of Endothelin 
Receptor Inhibition with Tezosentan in Acute Heart Failure 
Study (VERITAS) trial have failed to show lasting positive 
effect on outcomes and clinical symptoms in patients 
with advanced HF (44-48). The Endothelin Antagonist 
Bosentan for Lowering Cardiac Events in Heart Failure 
(ENABLE) trial studied 1,000 patients with NYHA IIIB 
and IV treated with low-dose bosentan did not show 
differences in the primary endpoint of all-cause mortality 
and HF hospitalization (49). In fact, one study reported a 
high incidence of liver abnormalities (50). Non-randomized 
studies of selective ETA receptor antagonists darusentan 
and sitaxsentan in patients with HFrEF have demonstrated 
improved hemodynamics without substantial side effects 
(51,52). However, in the Endothelin A Receptor Antagonist 
Trial in Heart Failure (EARTH) trial, darusentan did not 
provide a sustainable benefit on LV remodeling, morbidity 
or mortality in 642 patients with chronic HF (53). Due 
to the overall negative results from larger, randomized 
trials, the guidelines do not recommend use of the ERAs 
in patients with HF and PH (4,5,12). A randomized 
trial evaluating the safety and tolerability of macitentan, 
another non-specific ERA, in patients with Group 2 PH 
from HrEF is currently underway (54). Newer ERAs 
including ambrisentan and macitentan may have a better 
hepatic safety profile than bosentan and sitaxsentan, and it 
is unclear if there will be a role for these drugs in patients 
listed for OHT in the optimization of their PVR and TPG 
pre-transplant. One common class side-effect of ERAs is 
volume retention, which may complicate the treatment 
of HF. Additionally, it is unclear if these PAH specific 
medications would have a better safety profile and outcome 
if the patients were closely monitored with pulmonary 
artery catheters, ensuring their PCWP was <15 mmHg 
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during the use of off-label PAH medication.
Phosphodiesterase 3 (PDE3) inhibitors
PDE3 inhibitors such as milrinone and enoximone 
cause direct vasodilation in the pulmonary and systemic 
circulation, predominantly increasing flow with smaller 
changes in TPG (17). Despite these nearly instantaneous 
hemodynamic effects, this class of medications has not been 
shown to improve clinical outcomes, and, in fact, increases 
mortality in HF patients. Two large randomized trials with 
a combined >1,000 patients [The Prospective Randomized 
Milrinone Survival Evaluation (PROMISE) and The 
Studies of Oral Enoximone Therapy in Advanced Heart 
Failure (ESSENTIAL)] did not show benefit of these agents 
in patients with NYHA class III-IV HF (55,56). In addition, 
neither of these studies included patients listed for OHT.
Combination of medical therapy and mechanical 
support
A number of patients with medically refractory PH-
LHD have improved outcomes with the use of mechanical 
circulatory support. Seventy percent of this group are 
Table 2 Summary of randomized controlled trials of PDE-5 inhibitors and guanylyl cyclase agonists in patients with PH-LHD





Patient global assessment; 6-minute 












Change in peak oxygen consumption 
after 24 weeks of therapy
No statistically significant 




Tadalafil/Semigram/2013 HFrEF, 23 Composite outcome of CV mortality 
or HF hospitalization
Not reported
Sildenafil/Fernandes/2015 (36) HFrEF, 35 RV function, measured by CMR No statistically significant 
change in parameters; no 
improvement in left ventricular 
parameters or in the fractional 
area change of the pulmonary 
artery
LEPHT (37) Riociguat/Bonderman/2013 HFrEF, 
201
Placebo-corrected change from 
baseline at week 16 in mPAP
Primary endpoint not met; 
secondary endpoints: increase 
in cardiac index, decrease in 
PVR and SVR
DILATE-1 (38) Riociguat/Bonderman/2014 HFpEF, 36 mPAP at rest Primary endpoint not met; 
secondary endpoints: 
increased stroke volume, 
decreased systolic blood 






Change from baseline of cardiac 
output at rest, measured by right 
heart catheterization after 26 weeks 
of study drug treatment
Ongoing study
PH-LHD, pulmonary hypertension-left heart disease; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart 
failure with preserved ejection fraction; mPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance; SVR, systemic 
vascular resistance; CMR, cardiovascular magnetic resonance; CV, cardiovascular.
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successfully bridged to transplant and their clinical outcomes 
and survival are comparable at 30 days and 12 months 
to patients without out of proportion PH (12,57,58). 
Hemodynamic improvement is seen early after implant 
with mPAP and PVR decreasing significantly within days 
(58-62) .  Kutty  e t  a l .  [2013]  demonstrated  these 
hemodynamic changes in their study of 29 patients 
implanted with centrifugal LVADs. Baseline and post-VAD 
pulmonary hemodynamics were significantly improved. 
TPG was reduced from 14±3.9 to 9±3.3 mmHg and PVR 
decreased from 5±1.5 to 2.1±0.5 Wood units (P<0.05) 
post LVAD (58). These hemodynamic effects were also 
observed by John et al. [2010], in a cohort of 50 patients 
who received a continuous-flow HeartMate II LVAD. 
Mean PVR decreased significantly from a baseline of 
3.6±1.9 to 2.1±0.8 Wood units (P<0.001) (59). Etz et al. 
[2007] demonstrated not only improvement in post-VAD 
pulmonary hemodynamics but in addition more than half of 
the patients were successfully bridged to OHT (63). Mikus 
et al. followed 145 patients, studying the hemodynamic 
effects of circulatory support from time of implant to 
beyond 1 year. 56 patients had out of proportion PH, with a 
baseline PVR of 3.49±1.47 Woods units, which after LVAD 
support was reduced to 1.4±0.7 and 1.7±0.6 Wood units, 
at 6 and 12 months, respectively (60). There are currently 
no randomized clinical trials looking at the combined use 
of WHO group 1 PH medical therapies and LVAD in 
patients with out of proportion PH being optimized for 
OHT. Recent data suggest a benefit with the concomitant 
use of PDE-5 inhibitors, in particular sildenafil. In the 
perioperative setting, using sildenafil improves pulmonary 
hemodynamics and significantly increases cardiac 
output (64). Post LVAD implantation, weaning vasodilators 
such as NO could be challenging due to the side-effects of 
rebound PH and decreased RV function. With the addition 
of sildenafil, all patients in the study by Klodell et al. [2007] 
were weaned off NO and inotropic therapies. A lasting 
reduction in PA systolic pressure was observed as early as 90 
minutes after the administration of oral sildenafil (65). More 
than 40% of the patients in a study by Tedford et al. [2008] 
had reduced PVR <3–3.5 Wood units with the combination 
of LVAD and sildenafil therapy, allowing them to become 
OHT candidates (66). 
There are less published data on the effectiveness of 
inhaled vasodilators and ERA post-LVAD and prior to 
OHT. A small study of 7 patients post-LVAD demonstrated 
that administering NO and iloprost significantly reduced 
PVR, mPAP, RV systolic pressure, PCWP, and improved 
the efficiency of the assist device by increasing LVAD flow 
within 2 h after the initiation of these medications. In all 
seven patients, RVAD was avoided (67). In another study of 
bosentan, 50 consecutive patients were treated post LVAD. 
About 20% had to discontinue the medication because of 
side effects and the rest of the patients completed the study 
and had significant improvement in hemodynamics (68). 
Further studies are under way to explore the use of ERAs 
in patients with pre-existing PH-LHD and subsequently 
normalized PCWP, as is the case in post-LVAD or OHT. 
One such study which is enrolling will examine the efficacy 
and safety of macitentan in patients with PH after VAD in 
patients with RV failure (69). 
Conclusions
PH-LHD remains a significant risk factor for morbidity 
and mortality in patients being evaluated for OHT. A 
standardized classification and definition of the disease 
is still lacking, adding additional complexity for patient 
assessment and development of studies to assess treatment 
efficacy and safety. The sub-type of out of proportion PH-
LHD is difficult to treat and is associated with the worst 
patient outcomes. Several medical therapies mostly used in 
the treatment of WHO Group 1 PH have been used off-
label in the treatment of PH-LHD with varying success. 
To date, the most promising results in this category suggest 
that vasodilator therapies could be employed in the acute 
and perioperative settings and modulators of the guanylyl 
cyclase pathway could be used in more stable patients prior 
to OHT. Based on the available data we have presented, 
we propose a stepwise approach in the evaluation and 
management of patients with PH-LHD being evaluated 
for OHT (Figure 1). We hypothesize that there may be 
a role for group 1 PH therapies in the treatment of PH-
LHD after normalization of PCWP whether by standard 
HF medical therapy or mechanical circulatory support or 
the concomitant use of both. However, given the available 
evidence at this time, this review cannot justify the off-label 
use of Group 1 PH medications such as PDE-5 inhibitors, 
guanylyl cyclase stimulators, ERAs, or prostacyclins prior 
to OHT in the treatment of PH-LHD, unless it is part of 
a research protocol. The strongest evidence of treatment 
of PH-LHD prior to OHT remains the use of standard 
medical HF therapy and LVAD support. Future research 
and randomized clinical trials are needed to increase our 
understanding of the potential role of group 1 PH therapies 
as an additional strategy to optimize patients with PH-
2646 Koulova et al. Treatment of pulmonary hypertension in heart transplant candidates
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